English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Warfarin is the most widely used oral anticoagulant for the treatment of thromboembolic disorders and for stroke prophylaxis. Warfarin is a problematic drug because it exhibits large interindividual variation in the required therapeutic dose, has a narrow therapeutic range, and shows multiple food and drug interactions. Its anticoagulant effect is monitored by measuring the international normalized ratio (INR), which is a function of the time required for a patient’s blood to coagulate relative to the time it takes for a reference blood sample. Although warfarin has been used in humans for more than 50 years, its main side effect—bleeding—is a leading cause of hospital admission and drug-related death(1)(2). This problem has made patients and clinicians yearn for a new efficient and safe oral anticoagulant drug that does not require frequent monitoring. In Europe, a new oral anticoagulant drug (dabigatran) claimed to have these qualities has been licensed for short-term primary prevention of venous thromboembolic events, but its effectiveness in long-term secondary thromboprophylaxis remains to be shown. Furthermore, the daily cost of dabigatran is 5 times that of warfarin therapy including INR tests. To switch all warfarin patients (currently 1% of the population in many Western countries) to dabigatran would boost national costs in countries with subsidized drug programs; therefore, national authorities will probably encourage the continued use of warfarin, even when oral thrombin inhibitors become available for long-term thromboprophylaxis.Given that warfarin …

Point: Use of Pharmacogenetics in Guiding Treatment with Warfarin